HOME | ABOUT US | PRODUCTS & SOLUTIONS | ENZYMES | PROBIOTICS | APPLICATIONS | CAREERS | AETL MONITOR | CONTACT US
  
  
 Log in | Sign up
 
 


Leather Patent press-release
14th Feb'07


Coenzyme Q10 Definition

Coenzyme Q10 (CoQ 10) or ubiquinone is essentially a vitamin or vitamin-like substance. Disagreements on nomenclature notwithstanding, vitamins are defined as organic compounds essential in minute amounts for normal body function acting as coenzymes or precursors to coenzymes. They are present naturally in foods and sometimes are also synthesized in the body. CoQ10 likewise is found in small amounts in a wide variety of foods and is synthesized in all tissues. The biosynthesis of CoQ10 from the amino acid tyrosine is a multistage process requiring at least eight vitamins and several trace elements. Coenzymes are cofactors upon which the comparatively large and complex enzymes absolutely depend for their function. Coenzyme Q10 is the coenzyme for at least three mitochondrial enzymes (complexes I, II and III) as well as enzymes in other parts of the cell. Mitochondrial enzymes of the oxidative phosphorylation pathway are essential for the production of the high-energy phosphate, adenosine triphosphate (ATP), upon which all cellular functions depend. The electron and proton transfer functions of the quinone ring are of fundamental importance to all life forms; ubiquinone in the mitochondria of animals, plastoquinone in the chloroplast of plants, and menaquinone in bacteria. The term "bioenergetics" has been used to describe the field of biochemistry looking specifically at cellular energy production. In the related field of free radical chemistry, CoQ10 has been studied in its reduced form as a potent antioxidant.

Structure

History

CoQ10 was first isolated from beef heart mitochondria by Dr. Frederick Crane of Wisconsin, U.S.A., in 1957 (2). The same year, Professor Morton of England defined a compound obtained from vitamin A deficient rat liver to be the same as CoQ10(3). Professor Morton introduced the name ubiquinone, meaning the ubiquitous quinone. In 1958, Professor Karl Folkers and coworkers at Merck, Inc., determined the precise chemical structure of CoQ10: 2,3 dimethoxy-5 methyl-6 decaprenyl benzoquinone 1), synthesized it, and were the first to produce it by fermentation. In the mid-1960's, Professor Yamamura of Japan became the first in the world to use coenzyme Q7 (a related compound) in the treatment of human disease: congestive heart failure. In 1966, Mellors and Tappel showed that reduced CoQ6 was an effective antioxidant In 1972 Gian Paolo Littarru of Italy along with Professor Karl Folkers documented a deficiency of CoQ10 in human heart disease By the mid-1970's, the Japanese perfected the industrial technology to produce pure CoQ10 in quantities sufficient for larger clinical trials. Peter Mitchell received the Nobel Prize in 1978 for his contribution to the understanding of biological energy transfer through the formulation of the chemiosmotic theory, which includes the vital protonmotive role of CoQ10 in energy transfer systems

In the early 1980's, there was a considerable acceleration in the number and size of clinical trials. These resulted in part from the availability of pure CoQ10 in large quantities from pharmaceutical companies in Japan and from the capacity to directly measure CoQ10 in blood and tissue by high performance liquid chromatography. Lars Ernster of Sweden, enlarged upon CoQ10's importance as an antioxidant and free radical scavenger Professor Karl Folkers went on to receive the Priestly Medal from the American Chemical Society in 1986 and the National Medal of Science from President Bush in 1990 for his work with CoQ10 and other vitamins.

COENZYME Q10 DEFICIENCY

Normal blood and tissue levels of CoQ10 have been well established by numerous investigators around the world. Significantly decreased levels of CoQ10 have been noted in a wide variety of diseases in both animal and human studies. CoQ10 deficiency may be caused by insufficient dietary CoQ10, impairment in CoQ10 biosynthesis, excessive utilization of CoQ10 by the body, or any combination of the three. Decreased dietary intake is presumed in chronic malnutrition and cachexia.

The relative contribution of CoQ10 biosynthesis versus dietary CoQ10 is under investigation. Karl Folkers takes the position that the dominant source of CoQ10 in man is biosynthesis. This complex, 17 step process, requiring at least seven vitamins (vitamin B2 - riboflavin, vitamin B3 - niacinamide, vitamin B6, folic acid, vitamin B12, vitamin C, and pantothenic acid) and several trace elements, is, by its nature, highly vulnerable. Karl Folkers argues that suboptimal nutrient intake in man is almost universal and that there is subsequent secondary impairment in CoQ10 biosynthesis. This would mean that average or "normal" levels of CoQ10 are really suboptimal and the very low levels observed in advanced disease states represent only the tip of a deficiency "ice berg".

HMG-CoA reductase inhibitors used to treat elevated blood cholesterol levels by blocking cholesterol biosynthesis also block CoQ10 biosynthesisThe resulting lowering of blood CoQ10 level is due to the partially shared biosynthetic pathway of CoQ10 and cholesterol. In patients with heart failure this is more than a laboratory observation. It has a significant harmful effect which can be negated by oral CoQ10 supplementation

Increased body consumption of CoQ10 is the presumed cause of low blood CoQ10 levels seen in excessive exertion, hyper metabolism, and acute shock states. It is likely that all three mechanisms (insufficient dietary CoQ10, impaired CoQ10 biosynthesis, and excessive utilization of CoQ10) are operable to varying degrees in most cases of observed CoQ10 deficiency.

Clinical Applications

§ High blood pressure (hypertension)
Preliminary research suggests that CoQ10 causes small decreases in blood pressure (systolic and possibly diastolic). Low blood levels of CoQ10 have been found in people with hypertension, although it is not clear if CoQ10 "deficiency" is a cause of high blood pressure. It is not known what dose is safe or effective. CoQ10 is less commonly used to treat hypertension than it is for other heart conditions such as congestive heart failure. Well-designed long-term research is needed to strengthen this recommendation.

  • Alzheimer's disease
    Promising preliminary evidence from human research suggests that CoQ10 supplements may slow down, but not cure, dementia in people with Alzheimer's disease. Additional well-designed studies are needed to confirm this result before a firm recommendation can be made. Grade C

  • Angina (chest pain from clogged heart arteries)
    Preliminary small human studies suggest that CoQ10 may reduce angina and improve exercise tolerance in people with clogged heart arteries. Better studies are needed before a firm recommendation can be made.

  • Anthracycline chemotherapy heart toxicity
    Anthracycline chemotherapy drugs, such as doxorubicin (Adriamycin®), are commonly used to treat cancers such as breast cancer or lymphoma. Heart damage (cardiomyopathy) is a major concern with the use of anthracyclines, and CoQ10 has been suggested to protect the heart. However, studies in this area are small and not high quality and the effects of CoQ10 remain unclear.

  • Breast cancer
    Several studies in women with breast cancer report reduced levels of CoQ10 in diseased breast tissue or blood. It has been suggested by some researchers that raising CoQ10 levels with supplements might be helpful. However, it is not clear if CoQ10 is beneficial in these patients, or if the low levels of CoQ10 may actually be a part of the body's natural response to cancer, helping to fight disease. Supplementation with CoQ10 has not been proven to reduce cancer, and has not been compared to other forms of treatment for breast cancer.

  • Cardiomyopathy (dilated, hypertrophic)
    There is conflicting evidence from research on the use of CoQ10 in patients with dilated or hypertrophic cardiomyopathy. Different levels of disease severity have been studied (New York Heart Association heart failure classes I through IV). Some studies report improved heart function (ejection fraction, stroke volume, cardiac index, exercise tolerance), while others find no improvements. Most trials are small or not well designed. Better research is needed in this area before a recommendation can be made.

  • Exercise performance
    The effects of CoQ10 on exercise performance have been tested in athletes, normal healthy individuals, and in people with chronic lung disease. Results are variable, with some research suggesting benefits, and other studies showing no effects. Most trials have not been well-designed. Better research is necessary before a firm conclusion can be drawn.

  • Friedreich's ataxia
    Preliminary research reports promising evidence for the use of CQ10 in the treatment of Friedreich's ataxia. Further evidence is necessary before a firm conclusion can be drawn.

  • Gum disease (periodontitis)
    Preliminary human studies suggest possible benefits of CoQ10 taken by mouth or placed on the skin or gums in the treatment of periodontitis. Improvements in bleeding, swelling, and pain are reported. However, available studies are small and not high quality. Better research is needed before a conclusion can be drawn.

  • Heart attack (acute myocardial infarction)
    There is preliminary human study of CoQ10 given to patients within three days after a heart attack. Reductions in deaths, abnormal heart rhythms, and second heart attacks are reported, although better research is needed before a firm conclusion can be drawn.

  • Heart conditions (mitral valve prolapse in children)
    There is early data to support the use of CoQ10 in children with mitral valve prolapse. Well-designed clinical trials are needed before a recommendation can be made.

  • Heart failure
    The evidence for CoQ10 in the treatment of heart failure is controversial and remains unclear. Different levels of disease severity have been studied (New York Heart Association classes I through IV). Several studies have shown benefits of coenzyme Q10 in people who have been diagnosed with chronic heart failure (with or without cardiomyopathy), including in transplant recipients. Some studies report improved heart function (ejection fraction, stroke volume, cardiac index, exercise tolerance), while others find no improvements. Most trials are small or not well designed. In some parts of Europe, Russia, and Japan, CoQ10 is considered a part of standard therapy for congestive heart failure patients. Better research is needed in this area, studying effects on quality of life, hospitalization, death rates, before a recommendation can be made.

  • Heart protection during surgery
    Several studies suggest that the function of the heart may be improved after major heart surgeries such as coronary artery bypass graft (CABG) or valve replacement when CoQ10 is given to patients before or during surgery. Better studies that measure effects on long-term heart function and survival are necessary before a recommendation can be made.

  • HIV/AIDS
    There is limited evidence that natural levels of CoQ10 in the body may be reduced in people with HIV/AIDS. There is no reliable scientific research showing that CoQ10 supplements have any effect on this disease.

  • Increasing sperm count (idiopathic spermatozoa)
    There is early evidence that supports the use of CoQ10 in the treatment of increasing sperm count and motility. Better studies are needed before a strong recommendation can be made.

  • Kidney failure
    There is initial data from one small trial to support the use of CoQ10 in the treatment of kidney (renal) failure. More research is needed before a recommendation can be made

  • Migraine
    There is fair evidence to support the use of CoQ10 treatment in migraine prevention or treatment. However, more well-designed studies are needed to confirm these findings.

  • Mitochondrial diseases and Kearns-Sayre syndrome
    COQ10 is often recommended for patients with mitochondrial diseases, including myopathies, encephalomyopathies, and Kearns-Sayre syndrome. Several early studies report improvements in metabolism and physical endurance in patients with these conditions after treatment with CoQ10, although most available research is not high quality or definitive. Better studies are needed before a strong recommendation can be made.

  • Muscular dystrophies
    Preliminary studies in patients with muscular dystrophy taking COQ10 supplements describe improvements in exercise capacity, heart function, and overall quality of life. Additional research is needed in this area.

  • Parkinson's disease
    There is promising human evidence for the use of CoQ10 in the treatment of Parkinson's disease. Better-designed trials are needed to confirm these results.

  • Diabetes
    Preliminary evidence suggests that CoQ10 does not affect blood sugar levels in patients with type 1 or type 2 diabetes, and does not alter the need for diabetes medications.

  • Huntington's disease
    There is negative evidence from studies that used CoQ10 in the treatment of Huntington's disease.

Standardization

Standardization involves measuring the amount of certain chemicals in products to try to make different preparations similar to each other. It is not always known if the chemicals being measured are the "active" ingredients. CoQ10 products sold in stores have been found to contain variable amounts of claimed ingredients. Early studies used low doses, while more recent research suggests that higher doses may be safe and have greater effects.

  1. Adults (18 years and older)
    A) By mouth (oral) :

    General : 50-1200 milligrams of CoQ10 have been taken in divided doses by mouth daily.

    B) On the skin (topical) :

    Gum disease (periodontitis) : 85 milligrams of CoQ10 per milliliter of soybean oil suspension has been applied to the surface of affected areas once weekly using a plastic syringe, in one study.

    C. Through the veins (intravenous) :
    Heart protection during surgery : Most studies of CoQ10 for heart protection during bypass surgery have used CoQ10 taken by mouth. One study used intravenous CoQ10, 5 milligrams per kilogram of body weight, given 2 hours prior to surgery. Safety is not clear. Any therapies used close to the time of surgery should be discussed with the surgeon and a pharmacist prior to starting.

  2. Children (younger than 18 years)
    There is not enough scientific information to recommend the safe use of Coenzyme Q10 in children. A qualified healthcare provider should be consulted before considering use.

Allergies
In theory, allergic reactions to supplements containing CoQ10 may occur.

Side Effects and Warnings

There are few serious reported side effects of CoQ10. Side effects are typically mild and brief, stopping without any treatment needed. Reactions may include nausea, vomiting, stomach upset, heartburn, diarrhea, loss of appetite, skin itching, rash, insomnia, headache, dizziness, irritability, increased light sensitivity of the eyes, fatigue, or flu-like symptoms.

CoQ10 may lower blood sugar levels. Caution is advised in patients with diabetes or hypoglycemia, and in those taking drugs, herbs, or supplements that affect blood sugar. Serum glucose levels may need to be monitored by a healthcare provider, and medication adjustments may be necessary.

Low blood platelet number was reported in one person taking CoQ10. However, other factors (viral infection, other medications) may have been responsible. Lowering of platelets may increase the risk of bruising or bleeding, although there are no known reports of bleeding from CoQ10. Caution is advised in people who have bleeding disorders or who are taking drugs that increase the risk of bleeding. Dosing adjustments may be necessary.

CoQ10 may decrease blood pressure, and caution is advised in patients with low blood pressure or taking blood pressure medications. Elevations of liver enzymes have been reported rarely, and caution is advised in people with liver disease or taking medications that may harm the liver. CoQ10 may lower blood levels of cholesterol or triglycerides. Thyroid hormone levels may be altered based on one study.

Organ damage due to lack of oxygen/blood flow during intense exercise has been reported in a study of patients with heart disease, although the specific role of CoQ10 is not clear. Vigorous exercise is often discouraged in people using CoQ10 supplements.

 

Amyloglucosidase
Bacterial Alpha Amylase
Co Enzyme Q 10
Dextranase
Fungal Alpha Amylase
Fungal Diastase
Fungal Lactase
Fungal Lipase
Glucoamylase
Glucose Oxidase
Hemicellulase
Invertase
Laccase
Malt Diastase
NattoSEB (Nattokinase)
Neutral Cellulase
Ox Bile Extract
Pancreatin
Papain
Pectinase
Pepsin
Peroxidase
Phytase
Protease
Pullulanase
Serratiopeptidase
Sucrase
Trypsin Chymotrypsin Mix
Xylanase

 

  

www enzymeindia
 
Copyright © - Enzymeindia.com 2006 - All Rights Reserved